Title:
METHOD FOR DETERMINING RESISTANCE OF MELANOMA TO CANCER TREATMENT
Document Type and Number:
WIPO Patent Application WO/2019/156111
Kind Code:
A1
Abstract:
[Problem] The purpose of the present invention is to realize an effective melanoma treatment by discriminating melanoma that exhibits resistance to cancer treatment. [Solution] The present invention relates, using the amount of expression of IL-34 protein or mRNA encoding same as an index, to a method for determining the resistance of melanoma to cancer treatment; a method for determining the suitability of a melanoma patient for treatment with an agent that lowers the resistance to cancer treatment; a method for determining the suitability of a melanoma patient for chemotherapy, radiation therapy, or immunotherapy; a kit for determining the resistance of melanoma to cancer treatment; and a kit for determining the suitability of a melanoma patient for treatment with an agent that lowers the resistance to cancer treatment.
Inventors:
SEINO KEN-ICHIRO (JP)
BAGHDADI MUHAMMAD (JP)
BAGHDADI MUHAMMAD (JP)
Application Number:
PCT/JP2019/004200
Publication Date:
August 15, 2019
Filing Date:
February 06, 2019
Export Citation:
Assignee:
UNIV HOKKAIDO NAT UNIV CORP (JP)
International Classes:
G01N33/68; A61K39/395; G01N33/574; A61K45/00; A61P35/00
Foreign References:
| JP2015516369A | 2015-06-11 |
Other References:
GIRICZ, O. ET AL.: "ABSTRACT 1885: Integrated epigenomic profiling reveals widespread demethylation in melanoma and points to the role of CSF1R-RUNX1 axis in resistance against BRAF inhibition", CANCER RESEARCH, vol. 76, no. 14, July 2016 (2016-07-01), pages 1 - 5, XP055629822, Retrieved from the Internet [retrieved on 20190423]
WEST, B. L. ET AL.: "ABSTRACT 552: Targeting brain tumors with PLX3397, an inhibitor of the CSF-1 receptor kinase", CANCER RESEARCH, vol. 71, no. 8, April 2011 (2011-04-01), pages 1 - 4, XP055629823, Retrieved from the Internet [retrieved on 20190423]
GIRICZ, O. ET AL.: "ABSTRACT 3332: Aberrant expression of CSF1R in melanoma is driven through an endogenous viral promoter and it contributes to malignant growth and the acquisition of resistance against BRAF inhibition", CANCER RESEARCH, vol. 77, no. 13, July 2017 (2017-07-01), pages 1 - 4, XP055629826, Retrieved from the Internet [retrieved on 20190423]
BAGHDADI. M. ET AL.: "Chemotherapy-Induced IL 34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells", CANCER RESEACH, vol. 76, no. 20, 22 August 2016 (2016-08-22) - 15 October 2016 (2016-10-15), pages 6030 - 6042, XP055629827
MOK, S. ET AL.: "Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy", CANCER RESEARCH, vol. 74, no. 1, 18 November 2013 (2013-11-18), pages 153 - 161, XP055515200, doi:10.1158/0008-5472.CAN-13-1816
HAN, N. ET AL.: "Enhanced IL -34 expression in Ni volumab-resistant metastatic melanoma", INFLAMMATION AND REGENERATION, vol. 38, no. 3, 5 March 2018 (2018-03-05), pages 1 - 5, XP055629832
GIRICZ, O. ET AL.: "The RUNX1/ IL -34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma", JCI INSIGHT, vol. 3, no. 14, 25 July 2018 (2018-07-25), pages 1 - 22, XP055629834
WEST, B. L. ET AL.: "ABSTRACT 552: Targeting brain tumors with PLX3397, an inhibitor of the CSF-1 receptor kinase", CANCER RESEARCH, vol. 71, no. 8, April 2011 (2011-04-01), pages 1 - 4, XP055629823, Retrieved from the Internet
GIRICZ, O. ET AL.: "ABSTRACT 3332: Aberrant expression of CSF1R in melanoma is driven through an endogenous viral promoter and it contributes to malignant growth and the acquisition of resistance against BRAF inhibition", CANCER RESEARCH, vol. 77, no. 13, July 2017 (2017-07-01), pages 1 - 4, XP055629826, Retrieved from the Internet
BAGHDADI. M. ET AL.: "Chemotherapy-Induced IL 34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells", CANCER RESEACH, vol. 76, no. 20, 22 August 2016 (2016-08-22) - 15 October 2016 (2016-10-15), pages 6030 - 6042, XP055629827
MOK, S. ET AL.: "Inhibition of CSF-1 Receptor Improves the Antitumor Efficacy of Adoptive Cell Transfer Immunotherapy", CANCER RESEARCH, vol. 74, no. 1, 18 November 2013 (2013-11-18), pages 153 - 161, XP055515200, doi:10.1158/0008-5472.CAN-13-1816
HAN, N. ET AL.: "Enhanced IL -34 expression in Ni volumab-resistant metastatic melanoma", INFLAMMATION AND REGENERATION, vol. 38, no. 3, 5 March 2018 (2018-03-05), pages 1 - 5, XP055629832
GIRICZ, O. ET AL.: "The RUNX1/ IL -34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma", JCI INSIGHT, vol. 3, no. 14, 25 July 2018 (2018-07-25), pages 1 - 22, XP055629834
Attorney, Agent or Firm:
IP-ASSIST PATENT OFFICE (JP)
Download PDF:
Previous Patent: WAVE POWER GENERATION SYSTEM
Next Patent: FLUID TREATMENT SYSTEM, INJECTION CONTAINER, AND RECOVERY CONTAINER　
Next Patent: FLUID TREATMENT SYSTEM, INJECTION CONTAINER, AND RECOVERY CONTAINER